Xanomeline

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Xanomeline
DrugBank Accession Number
DB15357
Background

Xanomeline is under investigation in clinical trial NCT02831231 (Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 281.42
Monoisotopic: 281.156183547
Chemical Formula
C14H23N3OS
Synonyms
  • Xanomeline
External IDs
  • LY246708

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Xanomeline.
AmbenoniumThe risk or severity of adverse effects can be increased when Ambenonium is combined with Xanomeline.
AmikacinThe therapeutic efficacy of Xanomeline can be decreased when used in combination with Amikacin.
AprotininThe risk or severity of adverse effects can be increased when Aprotinin is combined with Xanomeline.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Xanomeline.
BetaineThe risk or severity of adverse effects can be increased when Betaine is combined with Xanomeline.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Xanomeline.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Xanomeline.
CapreomycinThe therapeutic efficacy of Xanomeline can be decreased when used in combination with Capreomycin.
CapsaicinThe risk or severity of adverse effects can be increased when Capsaicin is combined with Xanomeline.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
9ORI6L73CJ
CAS number
131986-45-3
InChI Key
JOLJIIDDOBNFHW-UHFFFAOYSA-N
InChI
InChI=1S/C14H23N3OS/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3
IUPAC Name
5-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
SMILES
CCCCCCOC1=NSN=C1C1=CCCN(C)C1

References

General References
Not Available
KEGG Compound
C11767
ChemSpider
54797
BindingDB
50003359
ChEBI
10056
ChEMBL
CHEMBL21536
ZINC
ZINC000001532358
Wikipedia
Xanomeline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentSchizophrenia2
3RecruitingTreatmentSchizophrenia / Schizophrenia; Psychosis2
2CompletedTreatmentSchizophrenia1
1CompletedTreatmentSchizophrenia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0758 mg/mLALOGPS
logP3.76ALOGPS
logP3.77ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)6.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.25 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity81.73 m3·mol-1ChemAxon
Polarizability32.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 15:19 / Updated on February 21, 2021 18:55